US 11,608,491 C1 (12,851st)
Suspension system for adeno associated virus production
Xin Yu, Zhangiagang (CN); Xavier de Mollerat du Jeu, Encinitas, CA (US); Chao Yan Liu, Germantown, MD (US); Jian Liu, Frederick, MD (US); and Jonathan Zmuda, Frederick, MD (US)
Filed by LIFE TECHNOLOGIES CORPORATION, Carlsbad, CA (US)
Assigned to LIFE TECHNOLOGIES CORPORATION, Carlsbad, CA (US)
Reexamination Request No. 90/019,379, Jan. 17, 2024.
Reexamination Certificate for Patent 11,608,491, issued Mar. 21, 2023, Appl. No. 16/798,193, Feb. 21, 2020.
Claims priority of provisional application 62/809,407, filed on Feb. 22, 2019.
Ex Parte Reexamination Certificate issued on Feb. 20, 2025.
Int. Cl. C12N 7/00 (2006.01); C12N 1/06 (2006.01); C12N 15/86 (2006.01)
CPC C12N 7/00 (2013.01) [C12N 1/06 (2013.01); C12N 15/86 (2013.01); C12N 2750/14041 (2013.01); C12N 2750/14152 (2013.01)]
AS A RESULT OF REEXAMINATION, IT HAS BEEN DETERMINED THAT:
Claim 4 is cancelled.
Claims 1 and 18 are determined to be patentable as amended.
Claims 2, 3, 5-17 and 19-21, dependent on an amended claim, are determined to be patentable.
1. A method for adeno-associated virus (AAV) vector production, the method comprising:
(a) culturing mammalian cells in suspension culture;
(b) transfecting the mammalian cells with an AAV transfer vector using a transfection reagent [ , wherein the transfection reagent comprises a cationic lipid] ;
(c) contacting transfected cells with an enhancer;
(d) culturing the transfected cells in suspension culture for a period of time sufficient for expression of the AAV vector, thereby producing a transfected AAV cell culture; [ and]
(e) harvesting AAV from the transfected AAV cell culture;
wherein the enhancer comprises one or more of a histone deacetylase (HDAC) inhibitor, sodium propionate, and caffeine.
18. A method for adeno-associated virus (AAV) vector production, the method comprising:
(a) culturing mammalian cells in suspension culture;
(b) transfecting the mammalian cells with an AAV transfer vector using a transfection reagent [ , wherein the transfection reagent comprises a cationic lipid] ;
(c) contacting transfected cells with an enhancer;
(d) culturing the transfected cells in suspension culture for a period of time sufficient for expression of the AAV vector, thereby producing a transfected AAV cell culture; [ and]
(e) harvesting AAV from the transfected AAV cell culture, wherein the cells are not centrifuged prior to harvesting AAV.